

1 **Transcriptome analyses of the cortex and white matter of focal cortical dysplasia type**

2 **II: insights into disease mechanisms and tissue characterization**

3

4 Guilherme Rossi Assis-Mendonça MD, PhD¹, Maria Carolina Pedro Athié PhD², João Vitor

5 Gerdulli Tamanini MD¹, Arethusa de Souza¹, Gabriel Gerardini Zanetti BSc³, Patrícia Aline

6 Oliveira Ribeiro de Aguiar Araújo PhD², Enrico Ghizoni MD, PhD⁴, Helder Tedeschi MD,

7 PhD⁴, Marina Koutsodontis Machado Alvim MD, PhD⁴, Vanessa Simão de Almeida PhD²,

8 Welliton de Souza PhD², Roland Coras MD⁵, Clarissa Lin Yasuda MD, PhD⁴, Ingmar

9 Blümcke MD, PhD⁵, André Schwambach Vieira PhD³, Fernando Cendes MD, PhD⁴, Iscia

10 Lopes-Cendes MD, PhD², Fabio Rogerio MD, PhD^{1*}

11

12 ¹ Department of Pathology, School of Medical Sciences, University of Campinas

13 (UNICAMP), and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN);

14 Rua Tessália Vieira de Camargo, 126, 13083-887, Campinas, SP, Brazil.

15

16 ² Department of Translational Medicine, School of Medical Sciences, University of Campinas

17 (UNICAMP), and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN);

18 Rua Tessália Vieira de Camargo, 126, 13083-887, Campinas, SP, Brazil.

19

20 ³ Department of Structural and Functional Biology, Institute of Biology, University of

21 Campinas (UNICAMP), and the Brazilian Institute of Neuroscience and Neurotechnology

22 (BRAINN); Rua Monteiro Lobato, 255, 13083-862, Campinas, SP, Brazil.

23

24 ⁴ Department of Neurology, School of Medical Sciences, University of Campinas

25 (UNICAMP), and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN);

26 Rua Tessália Vieira de Camargo, 126, 13083-887, Campinas, SP, Brazil.

27

1 ⁵ Department of Neuropathology, University Hospital Erlangen, Schwabachanlage 6, 91054,
2 Erlangen, Germany.

3

4 ***Corresponding author:** Fabio Rogerio. Rua Tessália Vieira de Camargo, 126, 13083-887,
5 Campinas, SP, Brazil.

6 Phone: +55 19 3521-7541 / Fax: +55 19 3289-3897

7 E-mail: fabiorog@unicamp.br

8

9 **E-mail addresses**

10 gui.rossiam@gmail.com (GRAM); maria.athie@gmail.com (MCPA);

11 jvgtamanini@yahoo.com.br (JVGT); arethusas@gmail.com (AS); ggzanetti95@gmail.com

12 (GGZ); ribeirop@unicamp.br (PAORAA); ghizonie@gmail.com (EG);

13 htedeschi@hotmail.com (HT); marinakma@gmail.com (MKMA);

14 va.salmeida25@gmail.com (VSA); well309@gmail.com (WS); Roland.Coras@uk-

15 erlangen.de (RC); cyasuda@unicamp.br (CLY); bluemcke@uk-erlangen.de (IB);

16 vieira.as@gmail.com (ASV); fcendes@unicamp.br (FC); icendes@unicamp.br (IL-C),

17 fabiorog@unicamp.br (FR)

18

19 **Number of text pages:** 28

20 **Number of words** (from Introduction to Discussion): 4 604

21 **Number of references:** 40

22 **Number of figures:** 8

23 **Number of tables:** 2

24 **ORCID numbers:**

25 Guilherme Assis-Mendonça (first author): 0000-0001-7644-4159.

26 Fabio Rogerio (corresponding and senior author): 0000-0001-5712-7617.

27

28

29

30

1

2

3

1 **ABSTRACT**

2 Focal cortical dysplasia (FCD) is a common cause of pharmaco-resistant epilepsy. According
3 to the 2022 International League Against Epilepsy classification, FCD type II is characterized
4 by dysmorphic neurons (IIa and IIb) and may be associated with balloon cells (IIb). We
5 present a multicentric study to evaluate the transcriptomes of the gray and white matters of
6 surgical FCD type II specimens. We aimed to contribute to pathophysiology and tissue
7 characterization. We investigated FCD II (a and b) and control samples by performing RNA-
8 sequencing followed by immunohistochemical validation employing digital analyses. We
9 found 342 and 399 transcripts differentially expressed in the gray matter of IIa and IIb lesions
10 compared to controls, respectively. The top enriched cellular pathway in IIa and IIb gray
11 matter was cholesterol biosynthesis, the genes *HMGCS1*, *HMGCR*, and *SQLE* being
12 upregulated in both type II groups. We also found 12 differentially expressed genes when
13 comparing transcriptomes of IIa and IIb lesions. Only 1 transcript (*MTRNR2L12*) was
14 significantly upregulated in FCD IIa. The white matter in IIa and IIb lesions showed 2 and 24
15 transcripts differentially expressed, respectively, compared to controls. No enriched cellular
16 pathways were detected. *GPNMB*, not previously described in FCD samples, was upregulated
17 in IIb compared to IIa and control groups. Upregulations of cholesterol biosynthesis enzymes
18 and *GPNMB* genes in FCD groups were immunohistochemically validated. Such enzymes
19 were mainly detected in both dysmorphic and normal neurons, whereas *GPNMB* was
20 observed only in balloon cells. Overall, our study contributed to identifying cortical
21 enrichment of cholesterol biosynthesis in FCD type II, which may correspond to a
22 neuroprotective response to seizures. Moreover, specific analyses in either the gray or the
23 white matter revealed upregulations of *MTRNR2L12* and *GPNMB*, which might be potential
24 neuropathological biomarkers of a cortex chronically exposed to seizures and of balloon cells,
25 respectively.

26

27

28

1

2 **Keywords**

3 Focal cortical dysplasia; Transcriptome; Cholesterol biosynthesis enzymes; Humanin-like 12;

4 GPNMB; Molecular biomarker; immunohistochemistry.

5

6

7

1 **1. Introduction**

2 Epilepsy is a neurological disease characterized by recurrent unprovoked seizures,
3 which may be caused by different brain disorders. Most patients have a satisfactory clinical
4 outcome with appropriate medications. However, seizures may be pharmacoresistant and
5 have detrimental and even life-threatening consequences (1,2). Around 30% of the patients
6 with focal epilepsies are candidates for surgical treatment, and their clinical outcome depends
7 on the pathological condition causing the seizures (3)The commonest causes leading to
8 medically intractable epilepsy are hippocampal sclerosis, long-term epilepsy-associated brain
9 tumors, and malformation of cortical development (MCD) (4). Particularly, MCDs represent a
10 wide range of lesions arising from the disruption of steps of cortical formation: cell
11 proliferation, cell migration, and cortical organization. Although the pathogenesis is still
12 unclear, specific genetic defects have been identified (5–7).

13 The incidence of MCDs in individuals submitted to epilepsy surgery varies among
14 centers. However, focal cortical dysplasia (FCD) is the most frequently reported MCD. FCD
15 is a structural lesion with different sizes, locations, and histopathological findings (7).
16 Clinically, seizure features depend on the FCD localization, and electroencephalography
17 mostly shows epileptiform discharges spatially correlated with the lesion. On magnetic
18 resonance imaging (MRI), FCDs may present with cortical thickening associated with
19 cortical–white matter junction blurring, a hyperintense signal on T2-weighted images, and an
20 abnormal pattern of sulci and gyri (1,4). Historically, the neuropathological classification of
21 FCD has been as variable as its broad morphological spectrum (4,7–9). Recently, the
22 International League Against Epilepsy (ILAE) has reviewed and updated its
23 neuropathological classification system for FCD. Specifically, FCD type II refers to isolated
24 lesions characterized by dyslamination of the cortex and dysmorphic neurons without (IIa) or
25 with balloon cells (IIb) (10,11).

26 The ILAE classification was expected to improve comparisons between
27 electroclinical, imaging and/or seizure control studies from different institutions and data
28 obtained from molecular investigations on the pathophysiology of FCDs (12). In this context,

1 we designed an original study in which transcriptome analysis (12) was performed to identify
2 differentially expressed mRNAs in the cortex and white matter of individuals with epilepsy
3 due to FCD type IIa or IIb. We compared the transcriptome profiles of the two lesions and
4 those obtained from control specimens from autopsied individuals without a history of
5 neurological disease. Immunohistochemical validation was performed for selected molecules.
6 We aimed to improve the current understanding of tissue findings associated with chronic
7 seizures and find potential FCD type II biomarkers by using RNA-Seq transcriptome analysis
8 to simultaneously evaluate a wide range of molecular pathways.

9

10

11 **2. Materials and Methods**

12 **2.1. Surgical samples and groups**

13 This is a retrospective study for which the samples were obtained in biorepositories
14 from both Institutions (University of Campinas, Brazil, and University Hospital Erlangen,
15 Germany). We obtained these samples from patients without the restriction of age or gender
16 but with previous confirmation that the surgical procedure involved the brain area with
17 clinically and MRI determined FCD. We evaluated only frontal lobes for transcriptome
18 analyses, as this is the most common location for FCD ILAE type II (13). We studied
19 additional specimens from other brain regions with histopathologic confirmation of FCD
20 ILAE type II for immunohistochemical validation. We obtained control samples from frontal
21 lobes of adults submitted to autopsy (between 6 and 12 hours *post mortem*) with neither
22 neurological disease nor a history of seizures. Details on clinical information and allocation of
23 surgical and control specimens for molecular and histopathological analyses are presented in
24 Tables 1 and 2.

25

26 **2.2. Brain sampling and neuropathological diagnoses**

1 Fresh brain samples were collected from surgical and autopsy specimens and (i)
2 formalin-fixed and paraffin-embedded (FFPE) or (ii) snap frozen in liquid nitrogen and stored
3 at -80°C.

4 FFPE samples were submitted to diagnostic routine, that is, evaluation of the cortical
5 cytoarchitecture and cellularity and myelination of the white matter in serial 4 µm-sections
6 stained with hematoxylin and eosin (H&E) and submitted to immunohistochemical reactions.
7 For the latter protocol, the sections were exposed to antibodies against NeuN (neuronal
8 marker; 1:1000, clone A60, Merck Millipore, cat#MAB377, Temecula, CA, USA), MAP2
9 (neuronal marker; 1:1000, clone M13, Thermo Fisher, cat#13-1500, Waltham, MA, USA),
10 SMI 32 (neuronal marker; 1:2500, clone SMI 32, Biolegend, cat#SMI-32R, San Diego, CA,
11 USA), GFAP (astrocytic marker, 1:100, clone 6F2, Dako/Agilent, cat#M0761, Santa Clara,
12 CA, USA), vimentin (1:100, clone V9, e-Bioscience/Thermo Fisher, cat#14-9897-82,
13 Waltham, MA, USA), CD34 (1:50, clone QBEnd-10, Dako, cat#M7165, Glostrup, Denmark)
14 and CNPase (myeloarchitecture marker; 1:500, clone 11-5 B, Millipore, cat#MAB326,
15 Darmstadt, Germany), for 18h at 4°C. Then, a detection solution containing the secondary
16 antibody and peroxidase (AdvanceTMHRP®, Dako, cat#K4068, Glostrup, Denmark; or
17 EnvisionTM Flex+, Dako, cat#K8002, Glostrup, Denmark) was added for 30 min at 37°C.
18 3,3-diaminobenzidine (DAB) was used as chromogenic substrate and counterstaining was
19 performed with hematoxylin. Negative controls (without primary antibody) were run
20 concurrently with all immunohistochemical reactions.

21 Samples exhibiting cortical dyslamination, hypertrophic and dysmorphic neurons
22 (disoriented neurons with anomalous cytoplasmic distribution of Nissl substance and
23 accumulation of non-phosphorylated neurofilament (SMI 32-positive)) without or with
24 balloon cells (large cells with opaque eosinophilic cytoplasm, vesicular nucleus and
25 immunopositivity for vimentin) were classified as FCD ILAE type IIa or IIb, respectively (10,
26 13). Samples from autopsies (control group) were submitted to the same protocol to exclude
27 microscopic alterations. All histological analyses were performed at regions of gyri

1 perpendicularly cut to the pial surface, as recommended by the FCD ILAE Classification (10,
2 13).

3

4 **2.3. Isolation of cortex and white matter and transcriptome analysis**

5 Frozen samples corresponding to previously evaluated FFPE sections were serially
6 cut (40 μ m), mounted in PEN membrane covered slides (Life Technologies), immediately
7 stained with Cresyl Violet and dehydrated with an ethanol series. The gray (cortical layer)
8 and white matters were mechanically dissected from 3 – 4 sections per sample with the aid of
9 a scalpel, collected in RNase-free individual tubes and stored at -80°C.

10 For cDNA library preparation and next-generation sequencing, total RNA from each
11 dissected sample was extracted and purified with Trizol (Thermo Fisher Scientific, cat #
12 15596018, Waltham, MA, USA). cDNA libraries were produced from extracted RNA (200
13 ng) by using the TruSeq Stranded total RNA kit (Illumina, San Diego, CA, USA) and
14 sequenced in a HiSeq 2500 platform (Illumina, San Diego, CA, USA) in High-Output mode,
15 producing 100-bp paired-end sequences. The amount (total number and number of sequences
16 produced per sample) and quality (% of bases over Q30) of the generated sequences were also
17 assessed. Sequence alignment was performed with STAR
18 (<https://github.com/alexdobin/STAR>) to *Homo sapiens* GRCh37/hg19 assembly.

19 The DESeq2
20 (<http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html>) package was used
21 for transcriptome analyses. A list of differentially expressed genes with a statistical
22 significance set at a $p < 0.05$ (after correction for multiple tests, *i.e.* adjusted p-value) was
23 generated. Such list was used for gene ontology analysis (calculation of enrichment of
24 pathways for the set of differentially expressed genes) by using Enrichr's web-based tools
25 (<https://amp.pharm.mssm.edu/Enrichr/>) (14,15). The results regarding the expression of genes
26 of interest were presented as Fold change, a simplified designation that refers to the \log_2 Fold
27 change calculation performed by the DESeq2 package when comparing the different groups
28 with each other.

1

2 **2.4. Sequencing Analysis of mTOR Pathway Genes**

3 We investigated the presence of somatic mutations in 68 genes of the mTOR pathway
4 in two specimens from which a blood sample was also available (11). We used genomic DNA
5 extracted from brain tissue surgically resected and compared it to sequences obtained from
6 the blood samples. We used the Sure Select Human All Exon V6 ® (Agilent, Santa Clara,
7 USA), followed by sequencing in a Hiseq 2500® (Illumina, San Diego, USA). Mosaicism
8 was evaluated by using Mutect2.20 (16) and Strelka2 (17). Only variants identified in both
9 programs were recorded. Somatic mosaicism was identified when <10% of reads were not
10 aligned to the human genome (GRCh37/hg19) and were present only in surgically removed
11 tissue sample. The impact of variants on protein function was analyzed by using SIFT,
12 Polyphen2, FATHMM, and MutationTaster (<http://sift.jcvi.org>;
13 <http://genetics.bwh.harvard.edu/pph2/>; <http://fathmm.biocompute.org.uk>;
14 <http://www.mutationtaster.org>). The classification recommended by the American College of
15 Medical Genetics and Genomics (18) was used to interpret sequence variants as implemented
16 in the Franklin™ software (GNX Data Systems, Inc., [https://franklin.genoox.com/clinical-](https://franklin.genoox.com/clinical-db/home)
17 [db/home](https://franklin.genoox.com/clinical-db/home)). We searched the variants identified in two control databases: GnomAD
18 (<https://gnomad.broadinstitute.org>) and BipMed (www.bipmed.org) (19).

19

20 **2.5. Immunohistochemical detection of proteins encoded by differentially expressed** 21 **genes**

22 For validation of the transcriptome results, 4µm-thick sections from FFPE specimens
23 were submitted to immunohistochemical reactions. The sections were incubated with primary
24 antibodies against HMGCS1, HMGCRCR, SQLE and GPNMB (please refer to item 3.4) for 18 h
25 at 4°C. Specifications of each antibody are as follows: HMGCS1 (1:500, polyclonal, Abcam,
26 cat# ab155787, Cambridge, United Kingdom), HMGCRCR (1:300, clone CL0260, Abcam, cat#
27 ab242315, Cambridge, United Kingdom), SQLE (1:300, polyclonal, Sigma-Aldrich/Merck,
28 cat#HPA020762, Darmstadt, Germany) and GPNMB (1:100, clone SP299, Abcam, cat#

1 ab227695, Cambridge, United Kingdom). Afterwards, the detection system containing
2 secondary antibody and peroxidase (AdvanceTMHRP®, Dako, cat # K4068, Glostrup,
3 Denmark) was added for 30 min at 37 °C. DAB was used as chromogenic substrate and
4 hematoxylin as counterstain. Negative controls (without primary antibody) were run
5 concurrently with all reactions.

6 Following the immunohistochemical reactions, all slides were scanned by using an
7 Aperio Scanscope CS2 (#23CS100) device. Ten representative pictures of each slide, at a
8 200x magnification, were chosen for the quantification of each marker, which was performed
9 in the ImageJ® software environment. The IHC Profiler plugin (20) was applied to each
10 image in the deconvolution step, that is, separation of hematoxylin and DAB channels. The
11 corresponding DAB channel picture was used for quantification via the “threshold” tool. A
12 threshold value was determined so that the histological findings in each picture were
13 preserved in the most accurate way considering the original photo. The final image consisted
14 of a black-and-white picture from which the percentage of positive pixels was obtained.

15 The Kruskal-Wallis test and the post hoc Dunn tests were performed with the
16 GraphPad Prism software (version 8.0) for statistical analyses. Statistical significance was set
17 at a $p < 0.05$.

18

19

20 **3. Results**

21 **3.1. Clinical and neuropathological data**

22 Seventeen FCD specimens from the UNICAMP (Brazil) and FAU (Germany)
23 biorepositories were assessed in the transcriptome study. Patients whose samples were
24 histopathologically assigned as FCD ILAE type IIa (n=9) or FCD ILAE type IIb (n=8) were
25 submitted to presurgical evaluation consisting of routine EEGs, video-EEG monitoring,
26 neuropsychological assessment, magnetic resonance imaging (MRI), and
27 Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and ictal Single-Photon
28 Emission Computed Tomography (SPECT) studies when indicated. Information on the

1 number of individuals per group and clinical data regarding gender, age at epilepsy onset, age
2 at surgery and epilepsy duration is shown in Table 1. All patients presented MRI features of
3 FCD type II that included focal cortical thickening, a varying degree of increased cortical and
4 subcortical signal intensity in T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR)
5 sequences, blurring of the gray-white matter junction, focal abnormal cortical gyration, and
6 cerebrospinal fluid cleft-cortical dimple (Fig. 1). The hyperintense T2-FLAIR signal in the
7 subcortical white matter with a wedge shape extending to the ipsilateral ventricle ependymal
8 surface (transmantle sign) was present in some but not all patients with FCD type IIb.

9 The neuropathological evaluation revealed samples with either cortical dyslamination
10 and dysmorphic neurons (FCD IIa diagnosis) or cortical dyslamination, dysmorphic neurons
11 and balloon cells (FCD IIb diagnosis). Gliosis and gray-white matter blurring in both FCD
12 types were shown by increased GFAP positivity and irregularly distributed CNPase
13 immunostaining, respectively. Heterotopic and dysmorphic neurons, as well as balloon cells,
14 were also observed in the white matter of FCD II samples (Fig. 2). Moreover, immature
15 CD34-positive cells were detected neither in the gray nor in the white matter.

16 Control specimens (n=4 for transcriptome analyses) were obtained from autopsied
17 individuals without a history of neurological diseases (clinical information is presented in
18 Table 2). Histological evaluation showed neither cortical dyslamination nor cytological
19 abnormalities in the gray and white matter. (Fig. 2).

20

21 **3.2. Transcriptome analysis**

22 Brazilian and German samples classified as FCD IIa were considered as one group
23 for gene expression analyses, the same for FCD IIb specimens. Regarding the gray matter
24 (cortical layer), a total of 342 and 399 differentially expressed genes were identified after
25 comparing FCD IIa and FCD IIb to controls, respectively. In the comparison between FCD
26 IIa and FCD IIb samples, we found 12 genes differentially expressed. Moreover, the principal
27 component analysis (PCA) dimensionality reduction method based on the RNA-Seq data
28 demonstrated that FCD IIa and FCD IIb samples aggregated in distinct clusters (Fig. 3).

1 An enrichment pathway analysis was performed for the differentially expressed genes
2 in FCD IIa or FCD IIb *versus* the control group by using the Enrichr tool. The main pathways
3 found considering the Panther 2016 database were Cholesterol biosynthesis, Ionotropic
4 glutamate receptor pathway, and Angiogenesis for FCD IIa. In FCD IIb, the main enriched
5 pathways were Cholesterol biosynthesis, Integrin signaling pathway, and Pyrimidine
6 metabolism (Fig. 3; enriched pathways and the corresponding differentially expressed genes
7 are presented as Supplementary Material).

8 When taking into account genes less frequently or not previously investigated in
9 human FCDs, we found upregulation of 3 cholesterol biosynthesis genes in FCDs, namely
10 *HMGCS1* (3-Hydroxy-3-Methylglutaryl-CoA Synthase 1; FCD IIa *vs* Control: Fold change =
11 0.92, adjusted p-value= 0.001; FCD IIb *vs* Control: Fold change = 0.98, adjusted p-value=
12 0.001); *HMGCR* (3-Hydroxy-3-Methylglutaryl-CoA Reductase; FCD IIa *vs* Control: Fold
13 change = 0.63, adjusted p-value= 0.005; FCD IIb *vs* Control: Fold change = 0.59, adjusted p-
14 value= 0.01); and *SQLE* (Squalene Epoxidase; FCD IIa *vs* Control: Fold change = 0.76,
15 adjusted p-value= 0.01; FCD IIb *vs* Control: Fold change = 0.89, adjusted p-value= 0.002)
16 (Fig. 3).

17 Moreover, a subsequent analysis focusing on the differentially expressed genes
18 between FCD IIa and FCD IIb showed that *MTRNR2L12* was the only upregulated transcript
19 in FCD IIa (FCD IIa *vs* Control: Fold change = 1.09, adjusted p-value = 0.0000003; FCD IIa
20 *vs* FCD IIb: Fold change = 0.67; adjusted p-value=0.05) (Fig. 3).

21 As regards the white matter, the comparison of FCD IIa and FCD IIb with the control
22 group showed a total of 2 and 24 differentially expressed genes, respectively. When
23 comparing FCD IIa and FCD IIb groups, we found 4 genes differentially expressed (Fig. 4;
24 Supplementary Material). No clustering of samples was identified by using the PCA method
25 and the corresponding RNA-Seq data. Similarly, the Enrichr tool found no enriched pathway
26 considering the three groups and the Panther 2016 database. Also, we performed analyses
27 focusing on differentially expressed genes not previously reported in human FCDs.
28 Particularly, *GPNMB* (glycoprotein nonmetastatic melanoma protein B) was upregulated in

1 FCD IIb vs Control (Fold change = 4.50, adjusted p-value = 0.03) and downregulated in FCD
2 IIa vs FCD IIb (Fold change = -5.68, adjusted p-value = 0.0000124) (Fig. 4).

3

4 **3.3. Sequencing Analysis of mTOR Pathway Genes**

5 This additional characterization refers to Individuals #13 and #14 with FCD type IIb
6 presented in Table 1. We found a variant classified as likely pathogenic in brain tissue
7 resected by surgery in one sample: gene *MTOR*, c.5930C>G, p.Thr1977Arg, 3% in tissue
8 resected by surgery, and 0% in blood (Individual #13). This variant has not been described in
9 control databases; however, it has been reported as a somatic mutation in tissue with focal
10 cortical dysplasia (FCD) (21) In addition, we found the variant c.4375G>C, p.Ala1459Pro,
11 2.4% in tissue resected by surgery and 0% in blood, classified as a variant of uncertain
12 significance (VUS) (Individual #14). This variant has not been reported in control databases
13 or samples with FCD.

14

15 **3.4. Immunohistochemical validation of the transcriptome results**

16 In this step, we used a total of 24 samples from Brazilian individuals (6 FCD IIa, 10
17 FCD IIb, and 8 controls; Tables 1 and 2). Considering the differential expressions of
18 *HMGCS1*, *HMGCR*, *SQLE* and *GPNMB* in FCD groups, we further evaluated
19 immunohistochemically the expression of the codified proteins by using available commercial
20 antibodies.

21

22 **3.4.1. HMGCS1, HMGCR and SQLE**

23 Immunostaining for the cholesterol biosynthesis enzymes HMGCS1, HMGCR and
24 SQLE showed a diffuse cytoplasmic pattern, mainly observed in normal and dysmorphic
25 neurons. Particularly, in FCD groups, immunopositive abnormal neurons were more
26 frequently observed than their normal counterparts. Balloon cells were virtually
27 immunonegative (Fig. 5).

1 Quantitative evaluation of HMGCS1 immunostaining by using the ImageJ® software
2 yielded the values 0.31 ± 0.32 (mean percentage value \pm standard deviation), 3.33 ± 1.08 , and
3 3.86 ± 2.02 for controls, FCD IIa and FCD IIb samples, respectively. Significantly higher
4 expressions were found in FCD IIa and FCD IIb compared to controls ($p=0.02$ and 0.002 ,
5 respectively). No difference was found after comparing FCD IIa and FCD IIb groups
6 ($p=0.99$) (Figs. 5 and 6).

7 As regards HMGCR, the values for controls, FCD IIa and FCD IIb were 0.10 ± 0.15 ,
8 1.27 ± 0.67 , and 2.34 ± 0.42 , respectively. A higher expression was observed in FCD IIb when
9 compared to controls ($p=0.0002$). No differences were found when comparing controls and
10 FCD IIa ($p=0.31$), as well as FCD IIa and IIb groups ($p=0.31$) (Figs. 5 and 6).

11 Values for SQLE immunostaining were 0.18 ± 0.26 , 1.87 ± 0.90 and 2.34 ± 0.64 for
12 controls, FCD IIa and FCD IIb groups, respectively. A higher expression of SQLE was found
13 when comparing FCD IIb with controls ($p=0.0008$). However, no differences were found
14 between FCD IIa and controls ($p=0.09$), as well as between FCD IIa and IIb ($p=0.99$) (Figs. 5
15 and 6).

16 Taken together, immunohistochemical detections of HMGCS1, HMGCR and SQLE
17 paralleled most of the upregulation of the corresponding transcripts in samples with FCD, as
18 compared to controls.

19

20 **3.4.2. GPNMB**

21 Immunopositivity for GPNMB was noted only in balloon cells. Most of them showed
22 diffuse cytoplasmic staining, which varied from light to dense. Some balloon cells, however,
23 were immunonegative. Normal and dysmorphic neurons showed no reactivity. Similarly,
24 other normal cell types (glia, endothelial and leptomeningeal) were negative for this marker.
25 Since immunohistochemical reactions were performed in sections containing both gray and
26 white matters, it was possible to identify immunopositive balloon cells in both compartments,
27 with a random distribution but predominantly in subpial and superficial white matter regions
28 (Fig. 7).

1 After quantitative assessment of GPNMB positivity by using the ImageJ® software,
2 the following values were verified in the superficial white matter for controls, FCD IIa and
3 FCD IIb groups: 0.002 ± 0.001 , 0.003 ± 0.001 , and 1.510 ± 0.810 , respectively. As regards
4 the deep white matter, the values for controls, FCD IIa and FCD IIb were: 0.002 ± 0.001 ,
5 0.002 ± 0.001 , and 1.07 ± 0.801 , respectively. When considering the superficial white matter,
6 significantly higher expression was found in FCD IIb compared to FCD IIa and controls,
7 ($p=0.02$ and $p=0.001$, respectively). No difference was found between FCD IIa and controls
8 ($p=0.99$). At the deep white matter level, no significant differences were found between the
9 groups (FCD IIa vs controls: $p=0.99$; FCD IIb vs controls: $p=0.07$; FCD IIa vs FCD IIb:
10 $p=0.09$) (Fig. 8).

11 The observation of GPNMB-positive balloon cells in the dysplastic cortical layer
12 prompted us to look for the corresponding gene expression in the gray matter transcriptome of
13 each group. Likewise, *GPNMB* was found to be significantly upregulated in FCD IIb vs
14 controls (Fold change = 1.08, adjusted p-value = 0.01) and downregulated in FCD IIa vs FCD
15 IIb (Fold change = -1.18, adjusted p-value = 0.04). *GPNMB* was not present in the list of
16 differentially expressed genes, when FCD IIa and control groups were compared (Figs. 7 and
17 8).

18 Quantitative evaluation of GPNMB immunostaining showed the values $0.002 \pm$
19 0.001 , 0.005 ± 0.005 , and 2.314 ± 1.632 for controls, FCD IIa and FCD IIb samples,
20 respectively. A higher expression was observed in FCD IIb when compared to controls and
21 FCD IIa ($p=0.002$ and $p=0.01$, respectively). No difference was found when comparing
22 controls and FCD IIa ($p= 0.99$) (Figs. 7 and 8).

23

24

25 **4. Discussion**

26 In this work, we aimed to generate additional insights into the molecular landscape of
27 FCD tissues by assessing the transcriptome profile, enriched cellular pathways, differential
28 gene expression, and protein synthesis in surgical samples from patients with FCD type II.

1 For this purpose, we designed an original protocol to dissect the gray and white matter and
2 evaluate each transcriptome by using a high-throughput sequencing method (RNA-Seq). Such
3 design aimed to avoid biases due to analyses performed with tissue homogenates from both
4 regions of the same sample (22). Overall, our results revealed different transcriptomic
5 signatures in FCD type IIa and IIb lesions. Of note, the RNA-Seq method allowed us to
6 obtain data not considered in previous studies focusing only on histopathological analyses of
7 human FCD samples. Thus, such genetic data prompted us to further histopathologically and
8 specifically investigate the expressions of cholesterol biosynthesis enzymes and GPNMB,
9 which are respectively potential neuropathological biomarkers of a dysplastic brain cortex
10 chronically exposed to seizures and of balloon cells.

11 Regarding the gray matter, we found enrichment of a wide range of cellular pathways
12 and the differential expression of 342 and 399 genes respectively in IIa and IIb groups
13 compared to controls. Therefore, we focused our discussion on genes not previously
14 described in human FCDs. In this sense, both FCD type II lesions showed enrichment of the
15 Cholesterol biosynthesis pathway and increased expression of *HMGCS1*, *HMGCR*, and
16 *SQLE*. Due to the lack of previous investigations on those genes, we decided to validate our
17 transcriptome results by performing immunohistochemical analyses of the codified proteins.

18 Cholesterol is a molecule with a wide range of functions, including cellular signaling
19 and stability, fluidity, and plasma membrane permeability. Cholesterol may be synthesized by
20 either neurons or glial cells in the central nervous system. Briefly, the initial steps involve 3-
21 Hydroxy-3-Methylglutaryl-CoA Synthase 1 (*HMGCS1*) conjugating acetyl-CoA with
22 acetoacetyl-CoA to synthesize 3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA), which is the
23 substrate for HMG-CoA Reductase (*HMGCR*) to produce mevalonate. Subsequently,
24 mevalonate is converted to squalene by Squalene Epoxidase (*SQLE*). In neurons, cholesterol
25 takes part in synaptogenesis and growth of dendrites and axons (23–25).

26 Here, the immunohistochemical analyses of *HMGCS1*, *HMGCR*, and *SQLE*
27 supported most of the upregulation of transcripts detected in FCD types IIa and IIb, compared
28 to controls. Particularly, we observed a higher percentage of immunopositivity for the three

1 enzymes in IIB lesions and HMGCS1 in IIA samples. The fact that the immunohistochemical
2 expression of the downstream enzymes HMGCR and SQLE did not parallel the gene
3 expression in IIA lesions may be due to molecular events associated with transcription and
4 translation processes, including abundances and degradation rates of mRNA and protein,
5 alternative splicing and post-translation changes (26–28). However, such cellular processes
6 did not seem to be discordant regarding the initial steps of cholesterol synthesis in FCD IIA,
7 since HMGCS1 immunoexpression was also higher in this lesion than in controls.

8 We, therefore, put forward the hypothesis that the enrichment of the cholesterol
9 pathway in the context of chronic seizures due to FCD may be a tissue response to the
10 imbalance in processes such as neurotransmission, synaptic vesicle exocytosis, and
11 maintenance of dendritic spines and axons. Furthermore, since cytotoxic-T cell infiltrates may
12 be observed in tissue from patients with FCD type II (29,30), cholesterol pathway enrichment
13 may be a response to minimize resident cell damage. Indeed, cholesterol-containing
14 lipoproteins secreted by glia cells exert anti-inflammatory and anti-apoptotic actions on glia
15 and neurons, respectively (24,31).

16 Furthermore, we found that *MTRNR2L12* was the only upregulated transcript in the
17 gray matter of FCD type IIA lesions compared to IIB. To the best of our knowledge, there are
18 no previous reports about *MTRNR2L12* expression in surgical samples from patients with
19 FCD. However, other authors have addressed studies on *MTRNR2* (also known as humanin)
20 and demonstrated that the expression of the corresponding protein in human neurons (32) was
21 associated with protective effects, such as anti-apoptotic by inhibiting BAX translocation
22 from the cytosol to mitochondria (33), antioxidant by increasing superoxide dismutase
23 activity (34), and preservation of synaptic connectivity by preventing dendritic atrophy
24 caused by glutamate (35). Thus, should *MTRNR2L12* exert similar functions to those
25 described for *MTRNR2*, it would be possible to consider a neuroprotective role for the
26 presently detected transcript in an abnormal cortical circuitry with dysmorphic neurons, no
27 balloon cells and chronically exposed to seizures. Future approaches could also investigate
28 the importance of *MTRNR2L12* as a diagnostic neuropathological marker of FCD type IIA.

1 The analysis of the white matter transcriptome of FCD type II lesions yielded no
2 results that we could straightforwardly associate with FCD or other brain malformations
3 causing epilepsy. However, a review of each of the differentially expressed genes showed that
4 *GPNMB* expression was significantly higher in the FCD IIb group than in FCD IIa and
5 controls. Notably, such gene codifies the glycoprotein nonmetastatic melanoma protein B
6 (GPNMB), a molecule that plays a role in motility processes, such as invasion and metastasis,
7 in poorly metastatic melanoma cells (36). Therefore, we hypothesized that this protein could
8 be relevant to the pathophysiology of FCD, a malformation in which abnormal cell migration
9 is also involved. Interestingly, the additional immunohistochemical investigation of GPNMB
10 in the current brain samples highlighted positivity virtually only in balloon cells.

11 As far as we know, there are no previous reports on GPNMB expression in FCD
12 surgical samples or experimental models. On the other hand, such protein has been described
13 to have neuroprotective, reparative, or anti-inflammatory actions in neurodegenerative
14 disorders (37–39) and cerebral ischemia-reperfusion injury (40) Under these circumstances,
15 GPNMB was found to be synthesized by neurons, astrocytes, and microglia in both human
16 and murine tissues. However, the corresponding pathophysiology mechanisms are still
17 debatable. Conversely, in our study GPNMB was only observed in balloon cells. Such
18 discrepancy with the mentioned reports could be due to technical matters, including primary
19 antibody clonality. Irrespective of tissue distribution differences between our study and those
20 from others, it is conceivable that GPNMB expression by balloon cells might be associated
21 with neuroprotection, cellular reparation, and anti-inflammatory action. As proposed above,
22 FCD type II may involve disruptions to neurotransmission and maintenance of neuronal
23 membrane structures and tissue inflammation (29,30).

24 A relevant finding of the current investigation is GPNMB as a potential diagnostic
25 neuropathological biomarker of balloon cells. In fact, we did not identify other cell types
26 (normal or abnormal) immunopositive for this molecule by using the primary antibody,
27 whose clone is SP299. Future studies with larger cohorts and different epilepsy centers are
28 necessary to validate such findings and support their use in the diagnostic routine. A potential

1 contribution would be to characterize better small surgical samples from individuals with
2 clinical neuroimaging diagnosis of FCD type IIB but whose neuropathological analysis only
3 shows dysmorphic neurons. In this context, the addition of anti-GPNMB antibody to the
4 currently recommended immunohistochemical markers by the ILAE (13) could help in the
5 search for balloon cells, thus, improving the histopathological work-up and classification of
6 the dysplastic cortex.

7 Somatic mutations in genes belonging to the mTOR pathway have been identified in
8 tissue from patients with FCD type IIB (11). Among the tissue samples studied in the present
9 work, we found two with somatic missense variants in the *MTOR* gene. One is a variant
10 previously linked to FCD type IIB (c.5930C>G, p.Thr1977Arg, (21)), the second is a novel
11 variant classified as VUS (c.4375G>C, p.Ala1459Pro). Although we cannot unequivocally
12 conclude that the c.4375G>C may be associated with FCD type IIB, we believe it is most
13 likely pathogenic since it has never been reported in control databases, including in an
14 ethnically matched database (www.bipmed.org; (19)). In addition, the in-silico prediction on
15 protein function indicates that the variant is probably/possible pathogenic by three of the four
16 algorithms used.

17 In conclusion, our study provides novel and high-quality data about gene expression
18 and enriched cellular pathways obtained from surgical samples of patients with FCD type IIA
19 and IIB. The current genetic and histopathological results, suggesting cellular events
20 associated with neuroprotection, may base future clinical and experimental approaches to
21 further understand the pathophysiological events associated with FCDs and tissue response to
22 seizures. Furthermore, upregulations of *MTRNR2L12* in FCD IIA and GPNMB in FCD IIB
23 might be potential neuropathological biomarkers of a brain cortex chronically exposed to
24 seizures and for balloon cells, respectively. Our results highlighted potential
25 pathophysiological mechanisms and contributed to tissue characterization of a frequent cause
26 of focal epilepsy.

27

28 **Conflict of interest disclosure**

1 The authors declare that they have no conflict of interest.

2

3 **Ethics Approval and Consent to Participate**

4 This study was performed according to Brazilian and German institutional ethical approvals
5 (UNICAMP - CEP#470/2003 and CAAE: 12112913.3.0000.5404; FAU - FP7 health
6 program, DESIRE grand agreement#602531). Written informed consent was obtained from
7 all participants.

8

9 **Author contribution statement**

10 FR, IL-C, FC, ASV, and IB contributed to the study design. GRAM, MCPA, JVGT, AS,
11 ASV, GGZ, PAORAA, EG, HT, MKMA, VSA, WS, CLY, RC, IB, FC, IL-C, and FR
12 obtained and analyzed the data. GRAM, JVGT, MCPA, ASV, IB, FC, IL-C, and FR drafted
13 the manuscript and figures. All authors reviewed and approved the final version of the
14 manuscript.

15

16 **Acknowledgements**

17 This study was sponsored by grants from Fundação de Amparo à Pesquisa do Estado de São
18 Paulo (FAPESP; 2013/07559-3, 2016/50486-5 and 2019/08259-0) and FAEPEX UNICAMP
19 (2037/19, 2428/20 and 2059/22).

20

21

22 **References**

- 23 1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al.
24 Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of
25 the ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2009 Nov 3;51(6):1069–
26 77.
- 27 2. Sander JW. The epidemiology of epilepsy revisited. *Current Opinion in Neurology*.
28 2003.

- 1 3. Widjaja E, Jain P, Demoe L, Guttmann A, Tomlinson G, Sander B. Seizure outcome
2 of pediatric epilepsy surgery. *Neurology*. 2020 Feb 18;94(7):311–21.
- 3 4. Blumcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien CG, et al.
4 Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. *New*
5 *England Journal of Medicine*. 2017 Oct 26;377(17):1648–56.
- 6 5. Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental
7 and genetic classification for malformations of cortical development. *Neurology*.
8 2005.
- 9 6. Avansini SH, Torres FR, Vieira AS, Dogini DB, Rogerio F, Coan AC, et al.
10 Dysregulation of NEUROG2 plays a key role in focal cortical dysplasia. *Ann Neurol*.
11 2018 Mar;83(3):623–35.
- 12 7. Aronica E, Becker AJ, Spreafico R. Malformations of Cortical Development. *Brain*
13 *Pathology*. 2012 May;22(3):380–401.
- 14 8. Taylor DC, Falconer MA, Bruton CJ, Corsellis JAN. Focal dysplasia of the cerebral
15 cortex in epilepsy. *Journal of Neurology, Neurosurgery & Psychiatry*. 1971 Aug
16 1;34(4):369–87.
- 17 9. Palmini A, Najm I, Avanzini G, Babb T, Guerrini R, Foldvary-Schaefer N, et al.
18 Terminology and classification of the cortical dysplasias. *Neurology*. 2004 Mar
19 23;62(Issue 6, Supplement 3):S2–8.
- 20 10. Najm I, Lal D, Alonso Vanegas M, Cendes F, Lopes-Cendes I, Palmini A, et al. The
21 ILAE consensus classification of focal cortical dysplasia: An update proposed by an
22 ad hoc task force of the ILAE diagnostic methods commission. *Epilepsia*. 2022;
- 23 11. Blümcke I, Coras R, Busch RM, Morita-Sherman M, Lal D, Prayson R, et al. Toward
24 a better definition of focal cortical dysplasia: An iterative histopathological and
25 genetic agreement trial. *Epilepsia*. 2021 Jun 1;62(6):1416–28.
- 26 12. Blumcke I, Cendes F, Miyata H, Thom M, Aronica E, Najm I. Toward a refined
27 genotype–phenotype classification scheme for the international consensus
28 classification of Focal Cortical Dysplasia. *Brain Pathology*. 2021 Jul;31(4).

- 1 13. Blümcke I, Thom M, Aronica E, Armstrong DD, Vinters H v., Palmini A, et al. The
2 clinicopathologic spectrum of focal cortical dysplasias: A consensus classification
3 proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission1.
4 *Epilepsia*. 2011 Jan;52(1):158–74.
- 5 14. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles G V., et al. Enrichr:
6 Interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC*
7 *Bioinformatics*. 2013;
- 8 15. Kuleshov M V., Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al.
9 Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.
10 *Nucleic Acids Res*. 2016;
- 11 16. Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling Somatic
12 SNVs and Indels with Mutect2. *bioRxiv* [Internet]. 2019 Jan 1;861054. Available
13 from: <http://biorxiv.org/content/early/2019/12/02/861054.abstract>
- 14 17. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, et al. Strelka2:
15 fast and accurate calling of germline and somatic variants. *Nature Methods*. 2018 Aug
16 16;15(8):591–4.
- 17 18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
18 guidelines for the interpretation of sequence variants: a joint consensus
19 recommendation of the American College of Medical Genetics and Genomics and the
20 Association for Molecular Pathology. *Genetics in Medicine*. 2015 May;17(5):405–24.
- 21 19. Rocha CS, Secolin R, Rodrigues MR, Carvalho BS, Lopes-Cendes I. The Brazilian
22 Initiative on Precision Medicine (BIPMed): fostering genomic data-sharing of
23 underrepresented populations. *npj Genomic Medicine*. 2020 Dec 2;5(1):42.
- 24 20. Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for
25 the quantitative evaluation and automated scoring of immunohistochemistry images
26 of human tissue samples. *PLoS One*. 2014;9(5):e96801.
- 27 21. D’Gama AM, Woodworth MB, Hossain AA, Bizzotto S, Hatem NE, LaCoursiere CM,
28 et al. Somatic Mutations Activating the mTOR Pathway in Dorsal Telencephalic

- 1 Progenitors Cause a Continuum of Cortical Dysplasias. *Cell Reports*. 2017
2 Dec;21(13):3754–66.
- 3 22. Kobow K, Ziemann M, Kaipananickal H, Khurana I, Mühlebner A, Feucht M, et al.
4 Genomic DNA methylation distinguishes subtypes of human focal cortical dysplasia.
5 *Epilepsia*. 2019 Jun;60(6):1091–103.
- 6 23. Hayashi H. Lipid metabolism and glial lipoproteins in the central nervous system.
7 *Biological and Pharmaceutical Bulletin*. 2011.
- 8 24. Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. *Protein and*
9 *Cell*. 2015;
- 10 25. Tracey TJ, Steyn FJ, Wolvetang EJ, Ngo ST. Neuronal lipid metabolism: Multiple
11 pathways driving functional outcomes in health and disease. *Frontiers in Molecular*
12 *Neuroscience*. 2018.
- 13 26. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from
14 proteomic and transcriptomic analyses. *Nature Reviews Genetics* [Internet].
15 2012;13(4):227–32. Available from: <https://doi.org/10.1038/nrg3185>
- 16 27. Wu L, Candille SI, Choi Y, Xie D, Jiang L, Li-Pook-Than J, et al. Variation and
17 genetic control of protein abundance in humans. *Nature* [Internet].
18 2013;499(7456):79–82. Available from: <https://doi.org/10.1038/nature12223>
- 19 28. Bauernfeind AL, Babbitt CC. The predictive nature of transcript expression levels on
20 protein expression in adult human brain. *BMC Genomics*. 2017 Dec 24;18(1):322.
- 21 29. Arena A, Zimmer TS, van Scheppingen J, Korotkov A, Anink JJ, Mühlebner A, et al.
22 Oxidative stress and inflammation in a spectrum of epileptogenic cortical
23 malformations: molecular insights into their interdependence. *Brain Pathology*. 2019
24 May 20;29(3):351–65.
- 25 30. Iyer A, Zurolo E, Spliet WGM, van Rijen PC, Baayen JC, Gorter JA, et al. Evaluation
26 of the innate and adaptive immunity in type I and type II focal cortical dysplasias.
27 *Epilepsia*. 2010;

- 1 31. Hayashi H. Lipid metabolism and glial lipoproteins in the central nervous system.
2 Biological and Pharmaceutical Bulletin. 2011.
- 3 32. Nishimoto I, Matsuoka M, Niikura T. Unravelling the role of Humanin. Trends in
4 Molecular Medicine. 2004.
- 5 33. Niikura T, Chiba T, Aiso S, Matsuoka M, Nishimoto I. Humanin: After the discovery.
6 Molecular Neurobiology. 2004.
- 7 34. Zhao ST, Huang XT, Zhang C, Ke Y. Humanin protects cortical neurons from
8 ischemia and reperfusion injury by the increased activity of superoxide dismutase.
9 Neurochemical Research. 2012;
- 10 35. Zárate SC, Traetta ME, Codagnone MG, Seilicovich A, Reinés AG. Humanin, a
11 mitochondrial-derived peptide released by astrocytes, prevents synapse loss in
12 hippocampal neurons. Frontiers in Aging Neuroscience. 2019;
- 13 36. Weterman MAJ, Ajubi N, van Dinter IMR, Degen WGJ, van Muijen GNP, Ruiters DJ,
14 et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines
15 and xenografts. International Journal of Cancer. 1995 Jan 3;60(1):73–81.
- 16 37. Nagahara Y, Shimazawa M, Ohuchi K, Ito J, Takahashi H, Tsuruma K, et al. GPNMB
17 ameliorates mutant TDP-43-induced motor neuron cell death. Journal of Neuroscience
18 Research. 2017 Aug;95(8):1647–65.
- 19 38. Hüttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, et al.
20 Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a
21 subset of activated microglia. Acta Neuropathologica Communications. 2018 Dec
22 19;6(1):108.
- 23 39. Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in
24 cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as
25 biomarkers and underpins importance of transcriptional pathways in amyotrophic
26 lateral sclerosis. Acta Neuropathologica. 2020 Jan 7;139(1):119–34.

1 40. Nakano Y, Suzuki Y, Takagi T, Kitashoji A, Ono Y, Tsuruma K, et al. Glycoprotein
2 nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in
3 cerebral ischemia–reperfusion injury. *Neuroscience*. 2014 Sep;277:123–31.

4

5

6 **Figure legends**

7 **Fig. 1** Preoperative coronal fluid-attenuated inversion recovery (FLAIR; a and c) and T1
8 inversion recovery (b and d), and axial FLAIR (e and g) and T1-weighted images (f and h) of
9 two patients with pharmacoresistant frontal lobe epilepsy whose surgical samples showed
10 focal cortical dysplasia (FCD) ILAE type IIa (a, b, e and f) and FCD type IIb (c, d, g and h).
11 In the patient with FCD IIa there is a discrete hyperintense signal of gray matter in T2/FLAIR
12 (yellow arrows in a and e), mild blurring of the gray-white matter junction in T1 scans, and a
13 cortical dimple indicated by the green arrow in e. The patient with FCD type IIb has a deep
14 sulcus with a mildly thickened cortex and hyperintense FLAIR signal in the left frontal lobe
15 (red arrows in c and g). ILAE: International League Against Epilepsy; L: left side; R: right
16 side

17

18 **Fig. 2** Representative histopathological and immunostaining features of autopsy (control),
19 focal cortical dysplasia (FCD) ILAE type IIa (FCD IIa) and FCD ILAE type IIb (FCD IIb)
20 samples. Hematoxylin and eosin staining (a-c; g-i; m-o). Immunohistochemistry for NeuN (d-
21 f; j-l) or CNPase (p-r). Cortical cytoarchitectural features, that is, layering and neuronal size
22 and orientation, are preserved in controls (a, d, g, j, m) specimens. However, dyslamination
23 (b, c, e, f, h, i, k, l, n, o) and dysmorphic neurons (green arrows in h, i, k, l) without and with
24 balloon cells (yellow arrows in i and l) are observed in FCD IIa and FCD IIb, respectively.
25 Gray matter (GM) and white matter (WM) boundary (dotted line in m-o and p-r) is preserved
26 in control samples (m and p) and blurred in FCD IIa (n and q) and FCD IIb (o and r). Scale
27 bars: 500 μ m (a-f), 20 μ m (g-l) and 50 μ m (m-r)

28

1 **Fig. 3** Gene expression analyses of the gray matter (cortical layer) of autopsy (control), focal
2 cortical dysplasia (FCD) ILAE type IIa (FCD IIa) and FCD ILAE type IIb (FCD IIb) samples.
3 a Graphical presentation of gene expression data after analyses performed with the PCA
4 dimensionality reduction method. Brazilian and German FCD specimens with the same
5 histopathological classification are shown as one group (FCD IIa or FCD IIb). Note that the
6 majority of FCD IIa samples tended to group together, as observed for FCD IIb cases. Each
7 circle corresponds to an individual sample. b Venn diagram showing the number of
8 differentially expressed genes in each group compared to controls. FCD IIa and FCD IIb
9 groups showed 342 and 399 differentially expressed genes, respectively. A total of 146 genes
10 were common to FCD IIa and IIb groups. The highest number of exclusively differentially
11 regulated genes was verified in FCD IIb (252). c Number of differentially expressed genes
12 when comparing the groups. d Graphs depicting the three main enriched pathways containing
13 the highest numbers of differentially expressed genes represented in the Venn diagram for
14 FCD IIa and FCD IIb (*vs* control group). Values presented in the X-axis correspond to
15 Enrichr $-\log(p\text{-value})$ by using Panther Pathways 2016 database. Pathways were considered
16 statistically significant when associated with values higher than $-\log(0.05) = 1.30$. Additional
17 data on enriched pathways and details on gene expression are reported in the Supplementary
18 Material. e Expression of the differentially expressed genes *SQLE*, *HMGCS1*, *HMGCR* and
19 *MTRNR2L12* in each group. Please refer to the text for details on fold change for each gene
20 and the corresponding statistical significance (adjusted p-value).

21

22 **Fig. 4** Gene expression analyses of the white matter of autopsy (control), focal cortical
23 dysplasia (FCD) ILAE type IIa (FCD IIa) and FCD ILAE type IIb (FCD IIb) groups. a
24 Graphical presentation of gene expression data after analyses performed with the PCA
25 dimensionality reduction method. Brazilian and German FCD specimens with the same
26 histopathological classification are shown as one group (FCD IIa or FCD IIb). Samples with
27 the same neuropathological diagnosis did not cluster together. b Venn diagram showing the
28 number of differentially expressed genes in each group compared to controls. FCD IIa and

1 FCD IIB groups showed 2 and 24 differentially expressed genes, respectively. Two genes
2 were common to FCD IIA and IIB groups. The highest number of exclusively differentially
3 regulated genes was verified in FCD IIB (22). c Number of differentially expressed genes
4 when comparing the groups. d Expression of the differentially expressed gene *GPNMB* in
5 each group. Please refer to the text for details on fold change and the corresponding statistical
6 significance (adjusted p-value). Additional data on gene expression are reported in the
7 Supplementary Material.

8

9 **Fig. 5** Immunohistochemical reactions for 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1
10 (HMGCS1), 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) and Squalene
11 Epoxidase (SQLE) in the cortical layer of control (a, g, m), focal cortical dysplasia (FCD)
12 ILAE type IIA (FCD IIA) (b, h, n) and FCD ILAE type IIB (FCD IIB) (c, i, o) specimens. In
13 FCD IIA and FCD IIB, a cytoplasmic staining was observed in dysmorphic neurons (green
14 arrows in b, c, h, i, n and o), in contrast with the negativity in balloon cells of FCD IIB lesions
15 (yellow arrows in c, i and o). Normal neurons (blue arrows in a, g, m) showed less noticeable
16 cytoplasmic positivity compared to the dysmorphic neurons. Digital images of the presented
17 immunohistochemical reactions were obtained by using the ImageJ® software (d-f, j-l, p-r).
18 In this setting, d-f, j-l and p-r correspond to the images shown in a-c, g-i and m-o,
19 respectively, after deconvolution and threshold steps. Note that the original
20 immunohistochemical findings (stained structures and tissue distribution) were preserved.
21 Scale bar: 100 μ m (a-r).

22

23 **Fig. 6** Quantification of the immunohistochemical expressions (percentage of positive pixels
24 per total number of pixels) of HMGCS1 (a), HMGCR (b) and SQLE (c) in the gray matter of
25 focal cortical dysplasia and controls. The graphs show scatterplots with superimposed median
26 and interquartile range (25-75). (*) $p < 0.05$; (**) $p < 0.01$ (Kruskall-Wallis test followed by
27 Dunn's post-hoc test).

28

1 **Fig. 7** Immunohistochemical reaction for GPNMB in control, focal cortical dysplasia (FCD)
2 ILAE Type IIa (FCD IIa) and FCD ILAE Type IIb (FCD IIb) specimens. The gray matter
3 (GM), superficial white matter (SWM) and deep white matter (DWM) are shown in a-f, g-l
4 and m-r, respectively. Immunopositivity was noted virtually only in balloon cells.
5 Particularly, the staining in such cells varied from null (red arrows in c) to intense (yellow
6 arrows in c, i, o). Both dysmorphic (green arrows in b and c) and normal (blue arrows in a)
7 neurons were negative. Digital images of the presented immunohistochemical reactions were
8 obtained by using the ImageJ® software (d-f, j-l, p-r). In this setting, d-f, j-l and p-r
9 correspond to the images shown in a-c, g-i and m-o, respectively, after deconvolution and
10 threshold steps. Note that the original immunohistochemical findings (stained structures and
11 tissue distribution) were preserved. Scale bar: 100 μ m (a-r).

12

13 **Fig. 8** Quantification of the immunohistochemical expression (percentage of positive pixels
14 per total number of pixels) of GPNMB in the gray matter (GM; a), superficial white matter
15 (SWM; b) and deep white matter (DWM; c) of focal cortical dysplasia and controls. The
16 graphs show scatterplots with superimposed median and interquartile range (25-75). (*)
17 $p < 0.05$; (**) $p < 0.01$ (Kruskall-Wallis test followed by Dunn's post-hoc test).








18



















19



20 **Supplementary Material** Transcriptome data (enriched pathways and gene expression) of
21 focal cortical dysplasia (FCD) ILAE type IIa (FCD IIa) and FCD ILAE type IIb (FCD IIb)
22 samples. Data of the gray and white matters are presented separately. Datasheets 1 and 2
23 show the enriched pathways, p-values and corresponding differentially expressed genes of the
24 gray matter of FCD IIa and IIb groups, respectively, versus controls (autopsy). Datasheets 3 –
25 8 present gene symbols (or Ensembl code when gene symbol was not available), Fold Change
26 (\log_2 fold change) values relative to the groups indicated in each datasheet designation, p-
27 values and adjusted p-values. Ctrl: control; GM: gray matter (cortical layer); WM: white
28 matter.

FCD IIa



FCD IIb



Control**FCD IIIa****FCD IIb**

a**b****c**

Groups		Number of differentially expressed genes (adjusted p value <0.05)
Control vs (n=4)	FCD IIa (n=7)	342
	FCD IIb (n=6)	399
FCD IIa vs (n=7)	FCD IIb (n=6)	12







d**e**

Control







FCD IIa

FCD IIb





HMGCS1






HMGCR



SQLC








Control

FCD IIa

FCD IIb

GM






d

e

f

SWM






j

k

l

DWM



p

q

r

